Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
Euvrard
Sylvie
S
Boissonnat
Pascale
P
Roussoulières
Ana
A
Kanitakis
Jean
J
Decullier
Evelyne
E
Claudy
Alain
A
Sebbag
Laurent
L
D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D002280:Basal Cell Carcinoma / Q000276:immunology / Q000517:prevention & control; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000517:prevention & control*; D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012878:Skin Neoplasms / Q000276:immunology / Q000517:prevention & control*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus